The following is a summary of “Clinical Impact of the CARMENA Trial on Cytoreductive Nephrectomy Practices in the USA: A ...

Dr. Mir discussed the role of cytoreductive nephrectomy in the immunotherapy era. Dr. Mir began by highlighting the following: All trials of cytoreductive nephrectomy are of patients with synchronous ...

My husband has late-stage stomach cancer, and we’ve heard there’s a new treatment for it, something called HIPEC. What is ...

A study based on a decade's worth of Korean insurance data found that use of direct oral anticoagulants (DOACs) to address ...

The phase 3 Shorespan-007 trial will compare bomedemstat with hydroxyurea in patients with treatment-naive essential ...

Ovarian cancers basically comprise of two types epithelial and non-epithelial ovarian malignancies. Epithelial ovarian cancer is the most prevalent type, accounting for more than 95%, while ...

Dr. Johnny Ong, MD, Associate Professor, Department of Sarcoma, Peritoneal and Rare Tumors, National Cancer Centre Singapore** commented: “One of the limitations of cytoreductive surgery (CRS) is the ...

In a recent study, researchers used high-throughput drug screening to identify potential therapeutic targets and novel ...

Real-World Primary Resistance to First-Line Immune-Based Combinations in Patients with Advanced Renal Cell Carcinoma (ARON-1). September 19, 2024 Upfront Versus Deferred Cytoreductive Nephrectomy in ...

The following is a summary of “Effect of postoperative normothermic intraperitoneal chemotherapy on the prognosis of MPM patients receiving CRS+HIPEC: a single-center case-control study,” published in ...

In The Lancet Respiratory Medicine, Eric Lim and colleagues published the anticipated results of the MARS 2 randomised trial, 1 which showed no benefit to cytoreductive surgical resection over ...